Amgen Inc (AMGN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Amgen ( AMGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.6%. By the end of trading, Amgen fell $2.69 (-2.4%) to $110.22 on average volume. Throughout the day, 2,623,164 shares of Amgen exchanged hands as compared to its average daily volume of 3,214,400 shares. The stock ranged in price between $110.08-$111.71 after having opened the day at $111.47 as compared to the previous trading day's close of $112.91. Other companies within the Drugs industry that declined today were: China Botanic Pharmaceutical ( CBP), down 98.2%, Atossa Genetics ( ATOS), down 46.4%, Mast Therapeutics ( MSTX), down 30.4% and Skystar Bio-Pharmaceutical Company ( SKBI), down 14.4%.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $86.5 billion and is part of the health care sector. Shares are up 33.2% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 254.8%, Cardiome Pharma Corporation ( CRME), up 24.9%, Cell Therapeutics ( CTIC), up 22.6% and Tekmira Pharmaceuticals Corporation ( TKMR), up 18.2%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback